Table 5 Results from sensitivity analysis of preadjusting the FPG measurements by a fixed value (2.5 mmol/L) per diabetes medication status.
SNP: Effect Allele: Trait | Gene | Phase | Effect SizeR | P-valueR | Effect SizeBMI | P-valueBMI |
|---|---|---|---|---|---|---|
rs1002487: C#, FPG | RPS6KA1: intronic | Discovery | 8.371 | 7.63E-08 | 8.48 | 4.78E-08 |
Replication | 3.378 | 1.27E-03 | 3.43 | 9.29E-04 | ||
Meta | 4.895 | 9.85E-07 | 6.201 | 5.59E-10 | ||
rs487321: A#, FPG | CADPS: intronic | Discovery | 6.041 | 1.01E-06 | 6.055 | 8.94E-07 |
Replication | 4.163 | 6.11E-06 | 4.092 | 7.35E-06 | ||
Meta | 6.396 | 1.59E-10 | 6.645 | 3.04E-11 | ||
rs707927: G@,$, FPG | VARS, VWA7: intron in VARS, 2 Kb upstream of VWA7 | Discovery | 1.011 | 6.34E-06 | 0.9928 | 8.93E-06 |
Replication | 0.6265 | 4.49E-04 | 0.5916 | 8.38E-04 | ||
Meta | 5.674 | 1.39E-08 | 5.502 | 3.75E-08 | ||
rs12600570: T@, FPG | DHX58: intronic | Discovery | 0.9928 | 8.93E-06 | 0.7241 | 1.7E-04 |
Replication | 0.4363 | 3.30E-03 | 0.4233 | 4.1E-03 | ||
Meta | 4.835 | 1.33E-06 | 4.803 | 1.56E-06 |
